VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE
January 27, 2000
Briefing Information
Antibody Responses to Hib Polysaccharide when used with NAVA DTaP, North American Vaccine Inc (NAVA)
"Brief Reports - Enhanced Immunogenicity of a Sequential Haemophilus Influenzae Type B Vaccine Schedule in Alaska Native Infants," The Pediatric Infectious Disease Journal, V 18, No. 11, Nov. 1999, p 1023-1024.*
Lucher, Lynne A. PhD, et al, "Special Feature from the CDC The Challenge of Ongoing2 Haemophilus Influenzae Type B Carriage and Transmission in Alaska," Alaska Medicine, Vol. 41, No. 3, July/Aug/Sept 1999, p 61-68.*
Gaiil, Karen, etc. "Reemergence of Invasive Haemophilus Influenzae Type b Disease in a Well-Vaccinated Population in Remote Alaska," JID., 179, January 1999, p 103-106.*
Eskola, Juhani, et al, "Review: Combined vaccination of Haemophilus Influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular/pertussis," The Lancet, Vol 354, December 11, 1999, p 2063-2068.*
Guess, Harry A. "Combination Vaccines: Issues in Evaluation of Effectiveness and Safety," Epidemiological Reviews, Vol 21, No. 1, p 89-95.*
Health, Paul T, "Haemophilus Influenzae type b conjugate vaccines: a review of efficacy data," Pediatric Infectious Disease Journal, 1998, Vol. 17, No. 9, p. S117-22.*
Decker, Michael D., MD et al, " Haemophilus Influenzae type b vaccines: history, choice and comparisons," Pediatric Infectious Disease Journal, 1998, Vol. 17, No. 9, p. S113-6.*
Zepp, F, et al "Immunology/Allergology: Evidence for induction of polysaccharide specific B-cell-memory in the 1st year of life: plain
Haemophilus Influenzae type b - PRP (Hib) boosters children primed with a tetanus-conjugate Hib-DTPa-HBV combinated vaccines," European Journal of Pediatrics, 1997 Vol 156, p 18-14.*
Granoff, D M, et al, "Induction of Immunologic Memory in Infants Primed with Haemophilus Influenzae type b Conjugate Vaccines," Journal of Infectious Diseases, 1993, Vol. 168, p 663-71.*
Goldblatt, D, et al, "antibody Avidity as a Surrogate Marker of Successful Priming by Haemophilus Influenzae type b Conjugate Vaccines following Infant Immunization," Journal of Infectious Diseases, 1998, Vol. 177, p 1112-5.*
Wenger, Jay D., MD, "Epidemiology of Haemophilus Influenzae type b disease and impact of Haemophilus Influenzae type b conjugate vaccines in the United States and Canada," Pediatric Infectious Disease Journal, 1998, Vol. 17, No. 9, p. S132-6.*
Jafari, Hamid S. et al, "Abstract - Efficacy of Haemophilus Influenzae type b Conjugate Vaccines and Persistence of Disease in Disadvantaged Populations," American Journal of Public Health, March 1999, Vol. 89, No. 3, p. 364-8.*
Comparative Immunogenicity Between Hib Combination Vaccines and Separately Injected Controls, FDA
Clinical impact of the DTPa-Hib interference, Juhani Eskola, KTL, Finland
Development of DTaP-based Hib conjugate combination vaccines: SmithKline Beecham
*This document contains copyrighted material. The document may be viewed at: Dockets Management Branch, Food and Drug Administration, 5630 Fishers Lane, Room 1061, Rockville, MD 20852